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Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system (CNS). Its prognosis
is one of the worst among all cancer types, and it is considered a fatal malignancy, incurable with conventional
therapeutic strategies. As the bioactive multifunctional lipid mediator lysophosphatidic acid (LPA) is well recognized
to be involved in the tumorigenesis of cancers by acting on G-protein-coupled receptors, LPA receptor (LPAR)
antagonists and LPA synthesis inhibitors have been proposed as promising drugs for cancer treatment. Six LPARs,
named LPA1–6, are currently recognized. Among them, LPA1 is the dominant LPAR in the CNS and is highly
expressed in GBM in combination with the overexpression of autotaxin (ATX), the enzyme (a phosphodiesterase,
which is a potent cell motility-stimulating factor) that produces LPA.
Invasion is a defining hallmark of GBM. LPA is significantly related to cell adhesion, cell motility, and invasion through the
Rho family GTPases Rho and Rac. LPA1 is responsible for LPA-driven cell motility, which is attenuated by LPA4. GBM is
among the most vascular human tumors. Although anti-angiogenic therapy (through the inhibition of vascular
endothelial growth factor (VEGF)) was established, sufficient results have not been obtained because of the increased
invasiveness triggered by anti-angiogenesis. As both ATX and LPA play a significant role in angiogenesis, similar to
VEGF, inhibition of the ATX/LPA axis may be beneficial as a two-pronged therapy that includes anti-angiogenic and
anti-invasion therapy. Conventional approaches to GBM are predominantly directed at cell proliferation. Recurrent
tumors regrow from cells that have invaded brain tissues and are less proliferative, and are thus quite resistant to
conventional drugs and radiation, which preferentially kill rapidly proliferating cells. A novel approach that targets
this invasive subpopulation of GBM cells may improve the prognosis of GBM. Patients with GBM that contacts the
subventricular zone (SVZ) have decreased survival. A putative source of GBM cells is the SVZ, the largest area
of neurogenesis in the adult human brain. GBM stem cells in the SVZ that are positive for the neural stem cell
surface antigen CD133 are highly tumorigenic and enriched in recurrent GBM. LPA1 expression appears to be
increased in these cells. Here, the author reviews research on the ATX/LPAR axis, focusing on GBM and an
ATX/LPAR-targeted approach.
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Glioblastoma multiforme (GBM) is the most highly ma-
lignant type of brain tumor. Despite the use of optimal
treatments and an evolving standard of care (maximal
safe resection with concurrent temozolomide (TMZ)
chemotherapy and radiation therapy), the median sur-
vival of patients diagnosed with GBM is only 12 to
16 months [1]. GBM cells are highly motile and invade
the normal brain parenchyma diffusely, resulting in poor
prognosis [2]. Because the blood-brain barrier (BBB) is
disrupted in GBM, some components in plasma or
serum may be able to affect the cell motility of GBM [3].
The most plausible components are considered to be
autotaxin (ATX) and lysophosphatidic acid (LPA). ATX
is a potent cell motility-stimulating factor that is identi-
cal to lysophospholipase D and that produces a bioactive
phospholipid, LPA, from lysophosphatidyl choline. ATX
is overexpressed in GBM. In addition, LPA1, the LPA re-
ceptor (LPAR) responsible for LPA-driven cell motility,
is predominantly expressed in GBM [4]. These import-
ant results suggest that the ATX/LPAR axis may be a
target for GBM therapy. Here, the author reviews
current results, focusing on the promising information
on the ATX/LPA/LPAR cascade that may lead to ameli-
oration of GBM.
Review
GBM and therapeutic difficulty
GBM is the most aggressive type of tumor of the central
nervous system (CNS), and its prognosis is one of the
worst among all cancer types. GBM has diffuse, invasive,
and highly angiogenic characteristics, which result in a
high recurrence rate. Following surgical resection, the
current standard of therapy involves concurrent admin-
istration of the DNA alkylating agent TMZ with radi-
ation, followed by adjuvant TMZ [1]. In addition to
TMZ, use of another agent, implants of biodegradable
polymers containing the alkylating agent carmustine,
was approved for clinical use. Although, a phase III trial
has suggested a modest survival benefit [5], the study
had several methodological problems and resulted in fre-
quent toxicities, such as brain edema, infection, and sei-
zures. A direct comparison of carmustine with standard
chemotherapy with TMZ is lacking [6]. For the treatment
of recurrent GBM, none of the available salvage treatments
has clearly shown improved survival [6]. The chemicals in
this class of alkylating agents are highly mutagenic. This re-
veals another aspect of a number of anti-cancer treatments:
in addition to their effects in reducing or eliminating tu-
mors, X-rays and certain traditional cytotoxic agents are
also carcinogenic, and their short-term success in produ-
cing clinical remission may be counterbalanced by the later
appearance of independently arising, second-site tumors
that are a consequence of their mutagenic action [7].Thus, at present, GBM is considered a fatal malig-
nancy that is incurable with conventional therapeutic
strategies. Given the resistance of GBM to conventional
therapeutic approaches, an urgent need exists to develop
alternative strategies to complement or improve current
approaches and improve long-term patient survival.
Strategies under development include novel adjuvant
chemotherapeutics to be combined with standard care,
as well as novel molecularly targeted approaches against
the tumor and its environment.
LPA, LPA receptors, and GBM
LPA (1- or 2-acyl-sn-glycerol 3-phosphate) is one of the
simplest natural phospholipids, consisting of a single
fatty acyl chain, a glycerol backbone, and a free phos-
phate group. LPA is a major active constituent of serum,
and unlike most other phospholipids, it is also water sol-
uble [8]. LPA is a main membrane-derived multifunc-
tional lipid mediator that is best known for its ability to
stimulate proliferation, migration, and survival of many
cell types, both normal and malignant [9]. LPA has been
implicated in the pathogenesis of several conditions, in-
cluding cancer [8], atherosclerosis and cardiovascular
disease [10, 11], Alzheimer disease [12], psychiatric
disorders such as schizophrenia and bipolar disorders
[13, 14], ischemic cerebrovascular disease [15], and
hydrocephalus [16].
LPA is a bioactive phospholipid that stimulates cell
proliferation, migration, and survival by acting on its
cognate G-protein-coupled receptor (GPCR). Aberrant
LPA production, receptor expression, and signaling
probably contribute to cancer initiation, progression,
and metastasis [8]. Although LPA production may par-
tially occur intracellularly, most LPA is produced extra-
cellularly by secreted enzymes. Three pathways mediate
the production of LPA: (1) cleavage of lysophophatidyl-
choline by lysophospholipase D (lysoPLD) in blood, (2)
deacylation of phosphatidic acid by phospholipase A2 in
inflammatory cells, activated platelets, endothelial cells,
and cancer cells, and (3) non-enzymatic, mild oxidation
of low-density lipoprotein [17, 18].
The primary molecular mechanism was reported in
1996 with the cloning of the first cognate receptor for
LPA [19]. Currently, at least six different LPA receptors
(LPARs; LPA1-LPA6) have been identified that share a
common GPCR structure [20]. All six receptors are
expressed throughout the body during development and
adulthood in unique spatiotemporal patterns [21].
Based on the amino acid sequence, LPA1-LPA3 share
50 % homology and belong to the endothelial differenti-
ation gene (Edg) family. Within the brain, LPA1 is the
most highly expressed, although LPA2 and LPA3 are also
present [20]. In 2003, Noguchi et al. successfully identi-
fied LPA4 (p2y9/GPR23) through ligand screening of
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ology with the human platelet-activating factor receptor,
a known GPCR [22]. The remaining LPARs, including
LPA4-LPA6, are structurally distinct from the Edg family
and are closely related to the purinergic receptor family
(non-Edg family) [23]. Non-Edg family members have a
higher affinity for alkyl-LPA species compared to the
Edg family members that have higher affinity for the acyl
variants [22].
Initial studies suggested that the brain is rich in LPA
and LPARs [24–26] and contains enzymes for the syn-
thesis and degradation of LPA [27]. LPA induces numer-
ous responses related to the morphological, pathological,
and clinical functions of the CNS [28–38]. The constant
level of LPA1 expression in undifferentiated and differen-
tiated astrocytes suggests that LPA1 primarily mediates
the LPA-induced stimulation of DNA synthesis [39].
LPA1-LPA3 are expressed at extremely low levels in the
normal adult brain, but expression is upregulated follow-
ing brain injury [40]. Following injury or ischemia of the
CNS, LPA activity increases in the cerebrospinal fluid
[41, 42]. LPA concentrations probably increase in the
CNS when the BBB is impaired, including after brain in-
jury, cerebral ischemia, and GBM. LPA1, the LPAR re-
sponsible for LPA-driven cell motility, is predominantly
expressed in GBM [4, 43].
ATX and GBM
ATX, a 125-kDa glycoprotein, is a multifunctional
phosphodiesterase that was originally isolated from
melanoma cells as a potent cell motility-stimulating
factor [44]. ATX is identical to lysoPLD and catalyzes
the production of LPA from lysophosphatidyl choline
[18]. ATX not only possesses lysoPLD activity, but it
also is a lipid carrier protein that efficiently transports
LPA to its receptors, LPA1-LPA6 [45]. All biological ef-
fects of ATX are thought to be attributable to LPA
production and subsequent receptor stimulation [46].
ATX is very widely expressed, with mRNA detected in
essentially all tissues including high levels of expression
in brain [47]. ATX is also present in plasma [9]. ATX is
highly expressed in a variety of cancers [48–52] includ-
ing GBM [53, 54], and is implicated in tumor progres-
sion, invasion, and angiogenesis. ATX overexpression in
GBM may facilitate invasion and migration through
endothelial cells in an autocrine manner, as well as pro-
mote neovascularization in the tumor core through
paracrine signaling [54].
Most brain cancer cells express high levels of ATX,
with the highest expression in the SNB-78 glioblastoma
cell line (derived from GBM) [4]. In addition, GBM
tissue samples derived from surgical specimens show ex-
tremely high ATX expression [4]. GBM may acquire its
high invasiveness through autocrine production of LPAby ATX [18]. Inhibition of ATX by its specific inhibitor
PF-8380 (Pfizer inflammation research, Missouri, USA)
leads to decreased invasion and enhanced radiosensitiza-
tion of GBM cells [55]. Furthermore, inhibition of ATX
leads to diminished tumor vascularity and delayed tumor
growth of GBM [55]. As a secreted phosphodiesterase,
ATX may be an attractive druggable therapeutic target
for GBM.
Angiogenesis, hypoxia, pseudopalisading necrosis, and LPA
GBM is among the most vascular human tumors [56].
Tumors require angiogenesis to maintain a constant nu-
trient supply. As the tumor grows, it disrupts pre-
existing blood vessels. Newly formed brain tumor blood
vessels possess a defective BBB that contributes to the
pathogenesis of tumor-associated edema [57], are
associated with an increased risk of intratumoral
hemorrhage [58], and are responsible for contrast en-
hancement on computed tomography and magnetic
resonance imaging [59].
Intravascular thrombosis within the tumor can clearly
accentuate and propagate tumoral hypoxia and necrosis.
Intravascular thrombosis within the tumoral tissue of
GBM is a frequent intraoperative finding by neurosur-
geons [60]. In many instances, intravascular thrombosis
is seen within or adjacent to the regions of pseudopali-
sading necrosis, leading to the proposition that vaso-
occlusion due to thrombosis may directly initiate or
propagate hypoxia and necrosis in GBM [60]. The plaus-
ible contributing factor of intravascular thrombosis in
GBM is access of plasma-clotting factors to tumoral
tissue. LPA plays a role in regulating platelet function
and thrombosis [11]. Plasma ATX is associated with
platelets during aggregation and is concentrated in arter-
ial thrombi [61].
Pseudopalisading necrosis has always been a histo-
pathological curiosity in GBM. No other tumor in
humans demonstrates such a histopathological alteration
[62]. Mamun et al. reported that cerebral ischemia/hyp-
oxia promotes rich pseudopalisading necrosis in a rat
model of glioblastoma [62] and a middle cerebral artery
occlusion modified from a reported method [63, 64].
Vascular occlusion and intravascular thrombosis lead to
tissue hypoxia in perivascular regions. The tumor cells
then become hypoxic and undergo apoptosis or necrosis,
eventually leading to a central necrotic zone [62]. Hyp-
oxic tumor cells produce angiogenic factors, the most
predominant of which is vascular endothelial growth fac-
tor (VEGF). Hypoxia also induces nuclear accumulation
of the hypoxia-inducible factor (HIF) alpha and beta
complex, resulting in transcriptional activation of VEGF
[65], and can upregulate expression of VEGFR2, a VEGF
receptor, in endothelial cells. VEGF signaling contributes
to the highly angiogenic nature of GBM [66].
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becomes important [67]. LPA stimulates cancer cell se-
cretion of VEGF and triggers angiogenesis [68]. Lee
et al. reported that LPA induces VEGF via HIF-1 alpha
activation [69]. Tissue hypoxia is a critical factor for
tumor aggressiveness and metastasis in cancers. HIF-1
alpha plays a critical role in enhancing and/or sensitizing
the role of LPA in cell migration and invasion in hypoxic
conditions [70]. Both LPA1 and LPA3 are involved in
LPA-induced VEGF secretion [71].
Bevacizumab, a monoclonal antibody that recognizes
VEGF, is currently clinically approved for GBM treat-
ment. Unfortunately, although bevacizumab treatment
prolongs progression-free survival in a subset of pa-
tients, only minimal improvements in overall survival
are observed, and patients invariably relapse [72, 73].
This may be explained by several previous observations.
As the brain is a highly vascular organ, GBM cells can
spread diffusely without necessarily requiring neovascu-
larization [74, 75]. Inhibition of tumor angiogenesis can
modulate patterns of tumor invasion [76, 77]. Increasing
evidence suggests that anti-angiogenic therapy can lead
to enhanced tumor cell invasion [76–79]. Although the
exact mechanisms responsible for this increased inva-
siveness are unknown, researchers have speculated that
a decreased supply of oxygen and nutrients may act as a
stimulus for tumor cell migration [80]. Lamszus et al.
reported an interesting double-pronged inhibitory regi-
men for this condition: a combined treatment directed
at VEGFR-2 and the epidermal growth factor receptor
(EGFR) [80]. This strategy simulates the ATX/LPA axis-
targeted approach. In addition to LPA, ATX plays a role
similar to that of VEGF in angiogenesis [81]. Thus,
inhibition of the ATX/LPA axis may be beneficial in
GBM as a double-pronged therapy that includes anti-
angiogenic therapy and anti-invasion therapy.
Invasion, cell motility, and LPA
Invasion is a defining hallmark of GBM, just as metasta-
sis characterizes other cancers. Drivers of GBM invasion
include autocrine signals propagated by secreted factors
that signal through receptors on the tumor. Various
autocrine motility factors are expressed by invasive
GBM cells. Most autocrine and paracrine interactions
involved in GBM invasion constitute known signaling
systems during CNS development that involve the mi-
gration of precursor cells that populate the developing
brain [82].
LPA1, the LPAR responsible for LPA-driven cell motil-
ity, is predominantly expressed in GBM [4]. The pattern
of invasion of GBM does not seem to be random, but ra-
ther seems to follow the path of blood vessels and more
prominently myelinated axons [83]. GBM usually in-
vades along white matter tracts. According to a studyusing post-mortem human brain tissue, in the normal
brain including the cortex and corpus callosum, LPA1 is
expressed in the white matter along fibers resembling
myelinated axons [84]. This is consistent with the pres-
ence of LPA1 on white matter tracts of adult mouse
brains and human cerebral cortex [85]. The LPA1 antagon-
ist Ki16425 (Kirin Brewery Co., Takasaki, Japan) effectively
suppresses LPA-induced motility of glioblastoma cells.
Thus, the motility of these cells appears to depend on ATX
and LPA1 [4]. LPA1-induced cell motility of GBM was also
shown in a previous report by Manning et al. [43].
Rho family GTPases including Rho and Rac are pre-
sumed to modulate various cellular functions such as
cytoskeletal reorganization, cell motility, invasion, and
proliferation. LPA is especially important in cell adhe-
sion, and LPA signaling has an obvious impact on both
focal adhesions (Rho) and lamellopodia (Rac) [86, 87].
Cell motility is tightly controlled by the activities of Rho
and Rac in a coordinated manner. The balance of Rho
and Rac activities is a critical determinant of cell move-
ment [88]. Each LPAR differentially contributes to these
activities.
Recently developed molecular targeted approaches to
GBM involving signaling pathways such as EGFR,
PDGFR, PI3K/AKT, and RAS predominantly address key
pathways involved in cell proliferation, whereas recur-
rent tumors regrow from the cells that have invaded the
brain and may be temporally less proliferative [83]. A
novel approach that targets this invasive subpopulation
of tumor cells and its environment will be necessary to
improve the prognosis of GBM. From this point of view,
the new treatment approach targeting LPA and LPAR
(LPA1) may be promising.
Subventricular zone (SVZ), neural stem/progenitor cells,
and LPAR
Migration is a phenomenon that is mainly present dur-
ing development [89]. In the adult CNS, the only cells
thought to maintain the capacity for motility are stem
cells or precursor cells in the subependymal layer that
may be recruited for regeneration and repair. Research
on human cancers including brain tumors has revealed
that tumor stem cells often constitute only a small pro-
portion (<5 %) of the neoplastic cells in these tumors.
Most of the cells in the neoplastic stem cell population
that are not actively dividing have proven to be quite re-
sistant to commonly used cytotoxic drugs, which prefer-
entially kill rapidly proliferating cells [7].
Cells originating from the stem-cell reservoir have been
hypothesized to be a source of glioma cells [90, 91]. Recent
evidence suggests that the heterogeneity seen in GBM may
be related to the cells of origin, which have stem cell-like
characteristics [92–94]. GBM contains a subset of stem-like
cells that express the gene for the neural stem cell surface
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propagation, and differentiation into multiple lineages [93,
95]. This population may play an important role in tumor
recurrence because they are resistant to chemotherapy and
radiation therapy and are capable of initiating tumors that
recapitulate GBM histology [92, 93]. A putative source of
glioma cells is the SVZ, the largest area of neurogenesis in
the adult human brain [96]. Neural stem cells (multipotent
neural progenitor cells) line the lateral ventricles in the
SVZ, and recruitment of these progenitor cells may play a
role in the aggressive behavior encountered in GBM [97].
In animal studies, the SVZ demonstrates increased suscep-
tibility to tumorigenesis compared with cortical regions
[98–100]. Experiments and clinical findings provide evi-
dence that neuronal progenitor cells in the SVZ with a high
migratory potential are involved in the aggressive GBM
subtype [101]. GBMs that contact the lateral ventricles have
been associated with multifocal dissemination [93, 102] and
worse overall survival than nonperiventricular GBMs [103].
Jafri et al. demonstrated that patients with GBM involving
the SVZ have decreased overall survival and progression-
free survival, which may have prognostic and therapeutic
implications [97]. A comparison of long-term survivors and
short-term survivors with GBM showed that tumor loca-
tion with regard to the SVZ is significantly associated with
survival [104].
The LPA1 receptor was originally identified from neur-
onal progenitor cells in the ventricular zone of the devel-
oping brain and was initially termed ventricular zone
gene-1 (vzg-1) [19]. Human neural progenitors express
functional LPARs that regulate cell growth and morph-
ology [105]. CD133(+) stem cells are highly tumorigenic
[106] and enriched in recurrent GBM [107]. Lysopho-
spholipids have been reported to regulate a diverse range
of stem cell processes including proliferation, survival,
differentiation, and migration in adult and embryonic
stem cells and progenitors [108]. LPA inhibits neuronal
differentiation of neural stem/progenitor cells derived
from human embryonic stem cells [109]. Expression of
the LPA1 receptor is increased in CD133(+) GBM stem
cells [110].
Taken together, LPAR (LPA1) may be significantly in-
volved in the aggressive behavior and poor prognosis en-
countered in GBM. Thus, therapies that target LPA1
may be potentially beneficial in GBM treatment, espe-
cially in preventing invasion, re-growth, and recurrence.
A novel potential therapeutic approach against GBM
Because LPA is well recognized to be involved in the
tumorigenesis and metastasis of a variety of cancers,
LPAR antagonists and LPA synthesis inhibitors (ATX in-
hibitors) have been proposed to be promising drugs for
cancer treatment [8]. Almost half of all drugs in current
use target members of the GPCR family, making LPARsattractive targets for therapeutic development. Structure-
function analysis, molecular modeling, and studies of
receptor structure are already contributing to the develop-
ment of novel receptor-selective antagonists [8]. As previ-
ously mentioned, the LPA1 antagonist Ki16425 (Kirin
Brewery Co., Takasaki, Japan) effectively suppresses the
LPA-induced motility of glioblastoma cells [4]. Ki16198
(Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan), which specif-
ically inhibits LPA1 and LPA3, is a promising orally active
LPAR antagonist for inhibiting the invasion and metastasis
of pancreatic cancer cells [111].
An LPA4 agonist is another possibility. LPA4 attenu-
ates LPA1-driven migration and invasion, indicating
functional antagonism between the two subtypes of
LPAR [112]. Thus, an LPA4-selective agonist may have
some beneficial effects for the treatment of GBM, al-
though the expression levels of LPA4 in GBM are rela-
tively low [4]. Although LPA4 (P2y9/GPR23) was
originally isolated from brain, high expression of LPA4 is
not detected in brain [22]. This may be explained by the
observation that specific types of cells in restricted areas
express LPA4. Rhee et al. reported that in an immortal-
ized hippocampal progenitor cell line, high-level expres-
sion of LPA1 and moderate-level expression of LPA4
were detected [113], suggesting that LPA4 may affect
LPA1 activity in brain tumors and/or their environment.
To determine the potential role of LPA1- and LPA4-tar-
geted compounds in GBM, the following questions re-
main to be answered in future studies. (1) How does
LPA1 react to various species of LPA within the tumor
environment, with and without VEGF inhibition? (2) Is
LPA4 expressed in neighboring astrocytes or the peri-
tumoral environment with regard to the helper nature of
mature astrocytes? (3) How will this expression affect
the progression of GBM? LPA species with both satu-
rated fatty acids (16:0, 18:0) and unsaturated fatty acids
(16:1, 18:1, 18:2, 20:4) have been detected in serum,
plasma, and activated platelets [114–116]. Interestingly,
these LPA species exhibit different biological activities
[117–119], possibly by the differential activation of the
different LPARs. For example, LPA with an unsaturated
fatty acid induces proliferation and de-differentiation of
smooth muscle cells, whereas LPA with a saturated fatty
acid does not [118, 119]. These observations clearly indi-
cate the biological significance of LPA species in vivo,
and they may influence GBM. Whether transactivation
of EGFR (by G12/13 activation from LPA) may also be
suppressed by an LPA1 antagonist remains unknown
and should be elucidated.
In addition to direct pharmacological modulation of
LPARs, several groups have targeted the upstream en-
zyme ATX for potential therapeutics. As ATX expres-
sion accounts for at least half of plasma LPA levels
[120], these drugs ultimately attenuate LPA signaling.
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clude the small molecules ONO-8430506 [121], PF-8380
[55], and gintoin, which is a plant-derived LPA/ginseng
glycolipoprotein complex that results in feedback inhib-
ition of ATX through LPAR signaling [122]. Whether
these inhibitors are reversible may also be an important
factor for actual clinical application.
A new type of multi-drug therapy in which several
drugs with synergistic effects are administered simultan-
eously may be beneficial. The potential benefits of tar-
geting ATX/LPAR were shown in murine breast cancer
models using a combination of an ATX inhibitor and an
LPAR antagonist [123]. Moreover, Schleicher et al. re-
ported that BrP-LPA, a novel dual-function pan-LPA
antagonist/ATX inhibitor, enhances radiation-induced
endothelial cell death, disrupts endothelial cell biological
function, and reduces glioma cell viability and migration
[124]. BrP-LPA treatment prior to irradiation represses
GBM tumor growth in vivo [124]. A monoclonal antibody
that specifically binds and neutralizes LPA has been devel-
oped and is in preclinical development [125, 126].
The predictable potential side effects of these drugs re-
quire careful attention. One report has shown that LPA1
deficiency leads to a schizophrenia-type pathology in
mice [85]. Such devastating side effects must be consid-
ered when developing new drugs. Designing new drugs
that can retain the desired effects, but not cause any un-
desirable effects, may be feasible. Currently, no approved
drugs targeting ATX/LPAR are available for clinical use.
A detailed analysis of the pharmacological properties of
synthetic inhibitors, including solubility, toxicity, pharma-
cokinetics, bioavailability, and permeability will be import-
ant in the effort to move these drugs into clinical use [127].
Clinical trials serve as the penultimate step on the path to-
ward clinical use in the treatment of human cancers includ-
ing GBM [128]. Several LPAR-specific analogues and small
molecules have been synthesized. To date, at least three
compounds have passed phase I and phase II clinical trials
for idiopathic pulmonary fibrosis and systemic sclerosis
[129–132]. Although no LPAR-targeting cancer drugs have
reached clinical trial stages thus far, pharmaceutical investi-
gation is progressing rapidly [21].
Finally, the author would like to propose a future puta-
tive protocol for treating GBM in the following order:
(1) Maximum tumor resection using multimodal intra-
operative information such as that provided by intraop-
erative neuroimaging, neuro-navigation, photodynamic
diagnosis, neurophysiological monitoring, histology, and
possibly photodynamic therapy during surgery; (2)
conventional radiation/TMZ therapy; (3) ATX and/or
LPAR-targeted therapy instead of TMZ maintenance
therapy; and (4) tumor removal or no tumor removal
followed by ATX and/or LPAR-targeted therapy in the
case of tumor recurrence. Theoretically, this protocolmay extend both progression-free survival and overall
survival of GBM patients compared to the present
standard therapy. The use of LPAR agonists/antagonists
and/or ATX inhibitors seems to be an attractive strategy,
and such drugs may be promising for the treatment of
GBM.
Conclusion
Therapeutic approaches targeting the ATX-LPA-LRAR
cascade may be a realistic addition to the treatment of
GBM in the near future.
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